<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362891</url>
  </required_header>
  <id_info>
    <org_study_id>NL73349.029.20</org_study_id>
    <nct_id>NCT04362891</nct_id>
  </id_info>
  <brief_title>Four Hyaluronic Acid Fillers for Lip Augmentation</brief_title>
  <official_title>Safety, Longevity and Patient Satisfaction Comparison of Four Hyaluronic Acid Soft Tissue Fillers in Lip Augmentation: Study Protocol for a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faceland Clinics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is need for evidence-based and reproducible data comparing the safety, longevity and&#xD;
      patient satisfaction propensity of the various HA soft tissue filler products. Among cosmetic&#xD;
      HA soft tissue filler procedures, especially the lip augmentation has become common.&#xD;
      Therefore, the aim of this study is to determine whether a statistically significant&#xD;
      difference can be detected in the safety, longevity and/or patient satisfaction related to&#xD;
      four HA soft tissue filler products widely used for cosmetic lip augmentation. Specifically,&#xD;
      the aim of this study is to determine whether superiority of one or more product(s) over the&#xD;
      others can be detected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Currently, hyaluronic acid (HA) soft tissue fillers are widely employed in&#xD;
      cosmetic medical practice for facial contouring and rejuvenation. Among these procedures,&#xD;
      especially the lip augmentation has become common. To this end various products have become&#xD;
      commercially available, however to date no robust evidence is available to support the&#xD;
      safety, longevity or patient satisfaction propensity superiority of one product over the&#xD;
      others.&#xD;
&#xD;
      Objective: To assess whether superiority in safety, longevity and patient satisfaction&#xD;
      propensity can be shown of one of four most frequently used FDA-approved and/or CE marked HA&#xD;
      fillers worldwide, used to augment the lip, over the others.&#xD;
&#xD;
      Study design: Multi-center, randomized, controlled, four group, parallel, triple-blind&#xD;
      clinical trial of 160 adult participants.&#xD;
&#xD;
      Study population: Consecutive healthy individuals with no history of previous lip treatment&#xD;
      and a self-reported wish for lip augmentation, who present at one of the private cosmetic&#xD;
      medicine clinics in the Netherlands, will be recruited.&#xD;
&#xD;
      Intervention (if applicable): After giving informed consent, participants will be randomized&#xD;
      to receive a protocoled lip augmentation procedure by the injection of either 1 mL of brand&#xD;
      A, B, C or D.&#xD;
&#xD;
      Main study parameters/endpoints: The primary outcome measure will be the absolute lip volume&#xD;
      augmentation as measured by the Lemperle Lip Index from baseline to 3-months follow-up.&#xD;
      Secondary outcomes will include the incidence of serious adverse reactions and side effects&#xD;
      related to the procedure, the absolute volume augmentation from baseline to 2-weeks follow-up&#xD;
      and self-reported quality of life and satisfaction with aesthetic results from baseline to&#xD;
      2-weeks follow-up as measured by validated FACE-Q questionnaire scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter; triple blind; randomized; parallel; controlled trial with 4 treatment arms (4 different widely used commercially available HA soft tissue fillers with FDA approval status and/or CE-marking for cosmetic facial use).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple (Participant, Care Provider, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Longevity of absolute lip volume augmentation</measure>
    <time_frame>from baseline to 3-months follow-up</time_frame>
    <description>The primary outcome will be the longevity of the absolute lip volume augmentation, as measured by the Lemperle Lip Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction (with lips)</measure>
    <time_frame>from baseline to 3-months follow-up</time_frame>
    <description>Patient satisfaction with the treatment as measured by validated FACE-Q questionnaire scores &quot;Satisfaction with Lips&quot; score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product safety (serious adverse events)</measure>
    <time_frame>baseline, 2-weeks and 3-months follow-up</time_frame>
    <description>Product safety, as measured by serious adverse events related to the procedure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life (Social)</measure>
    <time_frame>baseline to 3-months follow-up</time_frame>
    <description>Quality of Life as measured by validated FACE-Q questionnaire &quot;Social&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life (Psychological)</measure>
    <time_frame>baseline to 3-months follow-up</time_frame>
    <description>Quality of Life as measured by validated FACE-Q questionnaire &quot;Psychological&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction (with treatment outcome)</measure>
    <time_frame>from baseline to 3-months follow-up</time_frame>
    <description>Patient satisfaction with the treatment as measured by validated FACE-Q questionnaire scores &quot;Outcome&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction (with decision)</measure>
    <time_frame>from baseline to 3-months follow-up</time_frame>
    <description>Patient satisfaction with the treatment as measured by validated FACE-Q questionnaire &quot;Decision&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Product safety (impact of recovery from treatment)</measure>
    <time_frame>from 2-weeks to 3-months follow-up</time_frame>
    <description>Product safety, as measured by the FACE-Q questionnaire &quot;Early Life Impact&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Product safety (lip discomfort)</measure>
    <time_frame>baseline, 2-weeks and 3-months follow-up</time_frame>
    <description>Product safety, as measured by the FACE-Q questionnaire &quot;Lips&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Product safety (recovery symptoms)</measure>
    <time_frame>baseline, 2-weeks and 3-months follow-up</time_frame>
    <description>Patient satisfaction with the treatment as measured by validated FACE-Q questionnaire scores &quot;Recovery Early Symptoms&quot; score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute lip volume augmentation</measure>
    <time_frame>from baseline to 2-weeks follow-up</time_frame>
    <description>The absolute lip volume augmentation as measured by the Lemperle Lip Index.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Lip</condition>
  <arm_group>
    <arm_group_label>Juvéderm®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belotero®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stylage®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cosmetic lip augmentation</intervention_name>
    <description>The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.</description>
    <arm_group_label>Belotero®</arm_group_label>
    <arm_group_label>Juvéderm®</arm_group_label>
    <arm_group_label>Restylane®</arm_group_label>
    <arm_group_label>Stylage®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or over.&#xD;
&#xD;
          -  Female sex.&#xD;
&#xD;
          -  No history of previous lip augmentation treatment.&#xD;
&#xD;
          -  Oral and written informed consent to participate in the study.&#xD;
&#xD;
          -  Desire for cosmetic lip augmentation to improve one's physical or mental well-being.&#xD;
&#xD;
          -  Actively treatment seeking (patient actively chooses to make an appointment at a&#xD;
             Faceland private cosmetic clinic without invitation).&#xD;
&#xD;
          -  Small to moderately full lip volume (Merz Lip Scale score 0 - 2 out of 4).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active peri-oral infection in vicinity of injection site&#xD;
&#xD;
          -  Tumour in vicinity of injection site&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  History of severe hypersensitivity to filler components (sodium hyaluronate&#xD;
             preparations or local anesthetics of the -amide type, gram-positive proteins,&#xD;
             wasps/bees or the hyaluronidase enzyme)&#xD;
&#xD;
          -  Active collagenosis (e.g., active systemic lupus)&#xD;
&#xD;
          -  Graft vs. host disease&#xD;
&#xD;
          -  Active Hashimoto's disease&#xD;
&#xD;
          -  Use of thrombolytics or anticoagulants with high bleeding risk&#xD;
&#xD;
          -  General infection&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Untreated epilepsy&#xD;
&#xD;
          -  Keloid tendency&#xD;
&#xD;
          -  Cardiac arrythmia&#xD;
&#xD;
          -  Severe liver or kidney disease&#xD;
&#xD;
          -  Fulfilling the DSM-5 diagnostic criteria for Body Dyspmorphic Disorder&#xD;
&#xD;
          -  Concurrent laser- peeling- or dermabrasia treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan de Lange, MD DDS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serge Steenen, MD DDS</last_name>
    <phone>+31205667389</phone>
    <email>s.steenen@faceland.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan de Lange, MD DDS PhD</last_name>
    <phone>+31205667389</phone>
    <email>j.delange@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faceland Almere</name>
      <address>
        <city>Almere</city>
        <state>Flevoland</state>
        <zip>1314 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yama Hamraz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faceland Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5652 XR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Koeiman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faceland Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3011 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Steenen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faceland Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3565 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murielle van Engelen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Stojanovič L, Majdič N. Effectiveness and safety of hyaluronic acid fillers used to enhance overall lip fullness: A systematic review of clinical studies. J Cosmet Dermatol. 2019 Apr;18(2):436-443. doi: 10.1111/jocd.12861. Epub 2019 Jan 12.</citation>
    <PMID>30636365</PMID>
  </results_reference>
  <results_reference>
    <citation>Alam M, Kakar R, Nodzenski M, Ibrahim O, Disphanurat W, Bolotin D, Borovicka JH, Pace N, Alster TS, Arndt KA, Beer KR, Berlin JM, Bernstein LJ, Brightman LA, Butterwick K, Cox SE, Chotzen V, Fabi SG, Fitzpatrick RE, Geronemus RG, Goldman MP, Groff WF, Kaminer MS, Kilmer S, Rohrer TE, Tanzi EL, Silva SK, Yoo SS, Weinkle SH, Strasswimmer J, Poon E, Dover JS. Multicenter prospective cohort study of the incidence of adverse events associated with cosmetic dermatologic procedures: lasers, energy devices, and injectable neurotoxins and fillers. JAMA Dermatol. 2015 Mar;151(3):271-7. doi: 10.1001/jamadermatol.2014.2494. Erratum in: JAMA Dermatol. 2015 Feb;151(2):236.</citation>
    <PMID>25372511</PMID>
  </results_reference>
  <results_reference>
    <citation>Barone M, Cogliandro A, Cagli B, Persichetti P. FACE-Q Scales for Health-Related Quality of Life, Early Life Impact, Satisfaction with Outcomes, and Decision to Have Treatment: Development and Validation. Plast Reconstr Surg. 2015 Aug;136(2):272e-273e. doi: 10.1097/PRS.0000000000001439.</citation>
    <PMID>26218401</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. dr. J. de Lange</investigator_full_name>
    <investigator_title>Prof. dr. J. de Lange, Head of OMFS Surgery, Principal Investigator, Clinical Professor, at AUMC - location AMC</investigator_title>
  </responsible_party>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Dermal Fillers</keyword>
  <keyword>Lip</keyword>
  <keyword>Safety</keyword>
  <keyword>Longevity</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Patient Satisfaction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

